Show simple item record

dc.contributor.authorKoltowska-Häggström, Maria
dc.contributor.authorMattsson, Anders F
dc.contributor.authorShalet, Stephen M
dc.date.accessioned2010-02-09T10:55:06Z
dc.date.available2010-02-09T10:55:06Z
dc.date.issued2009-11
dc.identifier.citationAssessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. 2009, 161 Suppl 1:S51-64 Eur. J. Endocrinol.en
dc.identifier.issn1479-683X
dc.identifier.pmid19684056
dc.identifier.doi10.1530/EJE-09-0266
dc.identifier.urihttp://hdl.handle.net/10541/91513
dc.description.abstractQuality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAge Factors
dc.subject.meshAged
dc.subject.meshBiological Markers
dc.subject.meshConfounding Factors (Epidemiology)
dc.subject.meshDatabases, Factual
dc.subject.meshDrug Costs
dc.subject.meshFemale
dc.subject.meshHealth Resources
dc.subject.meshHuman Growth Hormone
dc.subject.meshHumans
dc.subject.meshHypopituitarism
dc.subject.meshInsulin-Like Growth Factor I
dc.subject.meshInternational Cooperation
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshQuality of Life
dc.subject.meshSex Factors
dc.titleAssessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations.en
dc.typeArticleen
dc.contributor.departmentKIMS Medical Outcomes, Pfizer Health AB, Endocrine Care, Sollentuna, Sweden. maria.koltowska-haggstrom@pfizer.comen
dc.identifier.journalEuropean Journal of Endocrinologyen
html.description.abstractQuality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.


This item appears in the following Collection(s)

Show simple item record